aTyr Pharma, Inc. (ATYR)

The past six months have included the announcement that the Phase 3 EFZO-FIT™ study of Efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint, leading to an 83.2% stock price decline on September 15, 2025, and subsequent class-action lawsuits. In August 2025, the company was added to the Russell 2000® and Russell 3000® Indexes. The company presented at the Piper Sandler 37th Annual Healthcare Conference in November 2025 and announced third-quarter 2025 results, including an update on the EFZO-FIT™ study and plans to meet with the FDA in the first quarter of 2026. The stock has experienced a significant decline of approximately 85.62% over the past six months.

As a clinical-stage biotherapeutics company, aTyr Pharma does not have traditional demand seasonality. Seasonality might be observed in investor interest or stock performance, influenced by sector trends and clinical trial timelines. The Healthcare sector has shown seasonal strength from April 25 to December 4. A seasonal chart analysis suggests a "Buy Date of August 27 and a Sell Date of December 2" has historically resulted in positive returns above the S&P 500 Total Return Index, but this is based on limited data. The company's financial performance is characterized by a pre-revenue stage, with significant R&D costs and negative net income and free cash flow.

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company focused on discovering and developing first-in-class medicines, leveraging its tRNA synthetase platform for therapies in fibrosis and inflammation. Their lead therapeutic candidate, Efzofitimod (ATYR1923), is in clinical development for interstitial lung disease (ILD), including pulmonary sarcoidosis and systemic sclerosis-related ILD (SSc-ILD), and has received orphan drug and fast track designations. The company's pipeline also includes ATYR0101 for fibrosis, ATYR0750 for liver disorders, as well as ATYR2810, NRP2 mAbs, AARS-1, and DARS-1.

aTyr Pharma, Inc. is headquartered in San Diego, California, United States. Clinical trials, including the Phase 3 EFZO-FIT study, have enrolled patients across multiple centers in nine countries, including North America, Europe, and Japan. aTyr Pharma has a license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of Efzofitimod for ILDs in Japan.

aTyr Pharma's brand reputation has been significantly impacted by the failure of Efzofitimod to meet its primary endpoint in the Phase 3 EFZO-FIT™ study in September 2025, resulting in a stock price drop and multiple class-action lawsuits alleging misleading statements. Analyst ratings for aTyr Pharma currently show a consensus "Hold" rating, with the company underperforming both the US Biotechs industry and the broader US Market over the past year.

aTyr Pharma's ownership is primarily composed of institutional investors, holding approximately 61.72% to 67.30% of the stock. Individual insiders own about 2.43% to 3.70%, while the general public and individual investors hold around 34.7% to 47.94%. Major institutional shareholders include Fmr Llc, Federated Hermes, Inc., BlackRock, Inc., Vanguard Group Inc., UBS Group AG, State Street Corp, Geode Capital Management, Llc, and Millennium Management Llc. Paul Schimmel is a significant individual insider owner.